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How organ-specific metastatic traits arise in primary
tumors remains unknown. Here, we show a role of the
breast tumor stroma in selecting cancer cells that are
primed for metastasis in bone. Cancer-associated
fibroblasts (CAFs) in triple-negative (TN) breast
tumors skew heterogeneous cancer cell populations
toward a predominance of clones that thrive on the
CAF-derived factors CXCL12 and IGF1. Limiting con-
centrations of these factors select for cancer cells
with high Src activity, a known clinical predictor of
bone relapse and an enhancer of PI3K-Akt pathway
activation by CXCL12 and IGF1. Carcinoma clones
selected in this manner are primed for metastasis in
the CXCL12-rich microenvironment of the bone
marrow. The evidence suggests that stromal signals
resembling those of a distant organ select for cancer
cells that are primed for metastasis in that organ,
thus illuminating the evolution of metastatic traits in
a primary tumor and its distant metastases.INTRODUCTION
A key question in understanding the origin of metastasis is how
cancer cells in a primary tumor acquire the ability to colonize a
particular distant organ. Primary tumors release large numbers
of cancer cells into the circulation, yet only a small proportion
of these cells survive the stress of invading distant organs and
progress to metastases (Chambers et al., 2002; Fidler, 2003;
Gupta and Massague´, 2006). Moreover, different tumor types
metastasize with distinct patterns of organ preference. It was
postulated that these metastatic traits are gained through
random prometastatic mutations in primary tumors and remain
rare until selection in secondary organ sites leading to expansion
of the mutant cell clones (Fidler, 1973; Nowell, 1976). In this1060 Cell 154, 1060–1073, August 29, 2013 ª2013 Elsevier Inc.model, the molecular determinants of metastasis would not be
overtly manifest in the bulk cell population of a primary tumor.
However, no driver mutations specific for metastasis to partic-
ular organs have been identified to date. Growing evidence
shows, on the contrary, that the likelihood of metastasis in gen-
eral, and ofmetastasis to certain organs in particular, can be pre-
dicted from gene expression patterns of primary tumors (Chang
et al., 2005; Chiang andMassague´, 2008; Minn et al., 2005; van ’t
Veer et al., 2002; Weigelt et al., 2003). These findings imply that
prometastatic activities expressed in large segments of the pri-
mary tumor cell population increase the probability that the can-
cer cells will colonize particular organs.
How organ-specific metastatic traits and their associated
gene signatures emerge in primary tumors remains an enigma
(Valastyan and Weinberg, 2011). A case in point is the specific
association of breast cancer bone metastasis with a gene
expression signature (Src response signature, SRS) that denotes
activation of Src and Src-dependent enhancement of PI3K-Akt
signaling in primary tumors (Zhang et al., 2009). This association
is particularly striking in the case of tumors that are triple nega-
tive (TN) for estrogen receptor (ER), progesterone receptor,
and ERBB2 amplification. As a group, TN tumors have a strong
propensity to metastasize in visceral organs, whereas SRS+
TN tumors additionally have a propensity to metastasize in
bone. Although Src can regulate many aspects of cell behavior,
its effect in models of breast cancer metastasis is to enhance the
survival and incipient outgrowth of metastatic cells that enter the
bone marrow, without affecting the rate of entry or the eventual
engagement of osteoclasts for osteolytic metastasis. Src pro-
motes the survival of breast cancer cells by amplifying the
responsiveness of the PI3K-Akt survival pathway to CXCL12
and IGF1 (Zhang et al., 2009). These cytokines are present in
the bone marrow stroma (Me´ndez-Ferrer et al., 2010) and are
more highly expressed in the bonemetastasis microenvironment
than in other metastatic sites (Zhang et al., 2009). Breast cancer
cells that lodge in the bone marrow are more likely to survive in
this environment if they possess Src-enhanced responsiveness
to these stromal cytokines.
Src hyperactivity, however, does not confer a net growth
advantage in mammary tumors (Zhang et al., 2009), nor is Src
frequently mutated or genomically amplified in breast cancer
(The Cancer Genome Atlas Network, 2012). These observations
raise questions about the mechanisms that lead to the accumu-
lation of Src-hyperactive cells in breast tumors. We addressed
these questions by considering two alternative hypotheses.
Src hyperactivity in SRS+ breast cancer cells could be biochem-
ically linked to the primary oncogenic alterations driving the
tumor or, alternatively, it could result from clonal selection of a
Src-dependent growth advantage that is not manifest in the pri-
mary tumor. Prior findings, which we confirmed, lent support to
the first of these hypotheses in ER+ breast tumors (Collins and
Webb, 1999) and HER2+ breast tumors (tumors driven by the
ERBB2 oncogene) (Ishizawar et al., 2007; Zhang et al., 2011).
However, our search for answers in the third major class of
breast cancer, TN tumors, revealed a process of stroma-driven
selection for clones that are primed for bone metastasis. This
process is driven by CXCL12 and IGF1 from mesenchymal stro-
mal cells, and it selects for Src-hyperactive cancer cell clones
that thrive in environments containing these signals. We delin-
eate this process of metastasis seed preselection in experi-
mental models and provide evidence for the existence of its
defining traits in human breast tumors.
RESULTS
Src Activation in Different Subtypes of Breast Cancer
To determine what drives Src activation in primary tumors, we
investigated the features associated with SRS+ status in
different subtypes of breast cancer. Most ER+ breast tumors
and at least half of HER2+ tumors score as SRS+ (Figure 1A; Fig-
ures S1A and S1B available online) (Zhang et al., 2009). Mecha-
nistically, this is in line with the ability of Src to interact with ER
and activate nontranscriptional tumorigenic signaling (Collins
and Webb, 1999) and the capacity of Src and ERBB2-ERBB3
dimers for reciprocal activation (Ishizawar et al., 2007; Zhang
et al., 2011). We confirmed these links with biochemical and
pharmacologic approaches (Figures S1C–S1H). We concluded
that Src activation, SRS+ status, and the propensity to metasta-
size in bone are intrinsically coupled to the oncogenic drivers in
these breast cancer subtypes (Figure 1A; Table S1).
TN breast tumors have a propensity to metastasize in visceral
organs. However, a significant proportion of these patients
develop metastasis to bone as the first site (Figure 1A; Table
S1) (Dent et al., 2009). SRS+ status in TN tumors is a strong prog-
nostic indicator of bone relapse (Zhang et al., 2009). Unlike the
ER+ and HER2+ subtypes, TN tumors are driven by diverse
oncogenic mutations. PIK3CA mutations are frequent in breast
cancer (The Cancer Genome Atlas Network, 2012). In the
TCGA breast cancer cohort, comprising 409 primary tumor sam-
ples with matched mutation and expression data, 43% of SRS+
tumors harbor PIK3CAmutations, versus 32% of all tumors (p =
2.73 105). Mutations in other PI3K pathway components such
as PTEN did not correlate with SRS status (p = 0.51). Within TN
tumors, 16% had PIK3CA mutations, versus 36% in the SRS+
TN subset (p = 0.00027), suggesting a limited contribution of
PIK3CA mutations to SRS+ status. Thus, SRS+ status repre-sents an output of diverse upstream mechanisms in TN breast
cancer.
CAF Content of TN Tumors Is Linked to BoneMetastasis
Seeking additional clues for how Src activity accumulates in
SRS+ TN tumors, we compared the gene expression profiles
of SRS and SRS+ TN tumors in independent clinical data
sets and focused on genes that are significantly enriched in
SRS+ tumors but are not part of the SRS gene set itself (Fig-
ure 1B). A total of 43 genes scored as SRS-associated genes,
among which 38 were validated in the TCGA data set (p <
0.001, FDR < 0.05; Figure 1B; Table S2). Notably, these genes
included CXCL12, CXCL14, IGF1, and IGF2 (Figure 1C), which
are also overexpressed in bone metastasis tissues compared
to metastases in lung, liver, or brain (Figure 1D) (Zhang et al.,
2009). The enriched expression of these four cytokines in ER
tumors was especially pronounced in TN cases compared to
HER2+ cases (Figure 1E). A two-gene classifier comprised of
CXCL12 and IGF1 alone was also prognostic of bone metastasis
(Figure 1F). These observations pointed at an intriguing resem-
blance in cytokine content between SRS+ TN tumors and the
bone marrow where these tumors preferably metastasize.
We sought to identify the source of these cytokines in SRS+
TN tumors. None of the TN breast cancer cell lines, including
MDA-MB-231 (MDA231 for short), CN34, BT549, MDA-MB-
435, or MDA-MB-436 cells, expressed a high level of CXCL12,
CXCL14, IGF1, or IGF2mRNAs (transcriptomic data not shown).
To determine whether the association of SRS with CXCL12/
CXCL14 and IGF1/IGF2mRNA expression in TN tumors reflects
an abundance of a particular cell type, we applied gene signature
classifiers that designate specific breast tumor stromal cell
types. These gene signatures were previously derived from puri-
fied cell populations from breast tumors of multiple patients
(Allinen et al., 2004) and, therefore, represent consensus profiles
of specific stromal types from individually heterogeneous
tumors. Notably, SRS+ status in TN tumors was associated
with a high score for fibroblast and myofibroblast gene signa-
tures, but not leukocyte or myoepithelial gene signatures (Fig-
ure 2A). Indeed, tumor-associatedmesenchymal cells (fibroblast
and myofibroblast), also referred to as cancer-associated fibro-
blasts (CAFs), abundantly express CXCL12 (Orimo et al., 2005).
In line with this, previous transcriptional data sets showed no
CXCL12 mRNA expression and low expression of IGF1 mRNA
in cancer cells compared to mesenchymal stroma (Allinen
et al., 2004).
The CAF gene set and the SRS-associated gene set included
CXCL12, CXCL14, and IGF1 (Figure 2B). Unsupervised hierar-
chical clustering by the combined mesenchymal stroma gene
signature (CAF signature for brevity) identified a set of TN tumors
comprising almost exclusively SRS+ cases (Figures 2C and
S2A). Gene set enrichment analysis (GSEA) confirmed this asso-
ciation (Figures 2D and S2B). Exclusion of tumors with PIK3CA
mutations did not diminish the correlation between CAF+ status
and SRS+ status (p = 0.0031, versus p = 0.004 for all tumors
included). Importantly, the CAF signature score of TN breast
tumors was tightly correlated with the content of stromal cells
staining positive for the CAF marker a smooth muscle actin
(aSMA) (Figures 2E and 2F). The SRS score was also associatedCell 154, 1060–1073, August 29, 2013 ª2013 Elsevier Inc. 1061
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Figure 1. Cytokine Similarities between SRS+ TN Breast Tumors and Bone Metastases
(A) Src activation in different breast cancer subtypes is shown. Upper panel illustrates hierarchical clustering by SRS, ER, and ERBB2 status of 615 primary breast
tumors with known bone metastasis outcomes. Red sticks indicate bone metastasis incidence. Lower panels show that, in ER+ tumors, ER in the cytoplasm
interacts with Src to trigger cell survival and proliferation (Collins and Webb, 1999). In HER2+ tumors, ERBB2-ERBB3 heterodimers signal cell proliferation and
survival by activating the PI3K-Akt pathway. Src potentiates the ERBB2-ERBB3 heterodimers, and conversely, ERBB2 activates Src (Ishizawar et al., 2007;
Zhang et al., 2011). The link to Src in TN tumors is unknown. Neg., negative; Pos., positive. See also Figure S1.
(B) Comparison of SRS+ and SRS tumors in the TN subtype to identify genes associated with SRS across independent data sets. EMC-MSK (GSE2603, 5327,
2034, and 12276), GSE7390, GSE4922, andGSE1456 data sets were used as discovery data sets, and TCGA data set was used as an independent validation set.
The corresponding sample sizes are indicated by pie charts.
(C) Genes that achieve significance (p < 0.001 and fold change >2) in the EMC-MSK data set were subjected to further analysis. For the EMC-MSK data set,
p values are log transformed and represented by the color scale. For other data sets, genes with p < 0.05 are indicated in red. All mapped genes are confirmed in
TCGA data set (p < 0.001 and FDR < 0.05; see Table S2).
(D) Venn diagram shows the overlap between cytokine genes enriched in bonemetastases and SRS-associated genes in primary tumors. The number of genes in
each category and the four overlapping genes are indicated.
(E) Microarray gene expression heatmap of the four cytokines within all ER tumors, including HER2+ and TN tumors. The lower heatmap shows unsupervised
clustering of ER/SRS+ tumors using the four cytokines and ERBB2. Red sticks indicate bone metastasis incidence.
(F) Kaplan-Meier plot illustrates the probability of cumulative bone metastasis (met)-free survival in patients with TN cancer according to CXCL12/IGF1
expression. Numbers of cases in each category are indicated in parentheses. p value was calculated according to log rank test.
See also Table S1.
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with the abundance of aSMA+ stromal cells (Figure S2C). The
CAF signature was overrepresented in bone metastases
compared tometastases at other sites (Figure 2G). These results
showed a concordance among CAF stromal content, CAF gene
signature score, and CAF-derived cytokines in TN SRS+ tumors.
Notably, both the CAF gene signature (Figures 2H and 2I) and
CAF cell content in TN breast tumors (Figures S2DandS2E) were
associated with bone relapse, but not with lung relapse. Thus, by
molecular and histological criteria, CAF-rich TN tumors were
predisposed to metastasize in bone. CAF signature (p = 0.027;
hazard ratio 2.36, 95%CI 1.24–4.47) and SRS (p = 0.023; hazard
ratio 7.11, 95% CI 1.87–27.10) as continuous variables also
correlated with bone relapse as the endpoint. An association of
the CAF signature with SRS+ status was also present though
less pronounced in ER+ and HER2+ tumors (Figure S2F). Collec-
tively, these results linked the CAF content with the propensity of
TN tumors to relapse in bone.
Premises for CXCL12 and IGF1-Driven Selection
The repeated observation of an association among SRS status,
CAF gene signature, CXCL12/IGF1 expression, and risk of
bone metastasis led us to consider the possibility of a selection
process whereby stroma-derived CXCL12 and IGF1 in breast tu-
mors skew cancer cell populations toward a preponderance of
Src-hyperactive clones and, thus, toward bone metastasis po-
tential. This ‘‘metastasis seed preselection’’ hypothesis required
three premises: first, the presence of a selectable trait—Src hy-
peractivity—in the cancer cells; second, a heterogeneous distri-
bution of this trait in the cancer cell population; and third, the
presence of limiting concentrations of CXCL12/IGF1 that would
act as a selector of cell fitness to respond to these survival
signals.
To determine the clonal distribution of Src activity in a hetero-
geneous breast cancer cell population, we analyzed the level of
activated Src (Src phosphorylated at Tyr416, pY416-Src) in 100
clonal cell lines isolated from the MDA231 parental population.
We quantitated the pY416-Src level in each clone by ELISA.
The distribution of values varied over a 12-fold range (Figure 3A).
These values remained stable over 25 population doublings in
culture (data not shown). Thus, pY416-Src was a heteroge-
neously distributed, stable trait in the cancer cell population.
To define CXCL12 and IGF1 as positive selectors, we deter-
mined the Akt response in cancer cells incubated with a range
of CXCL12 and IGF1 concentrations (Figure S3A). Based on
the sensitivity of Akt activation, we chose intermediate
(30 ng/ml CXCL12, 10 ng/ml IGF1) or saturating (300 ng/ml
CXCL12, 100 ng/ml IGF1) concentration of these factors and
determined their combined effect on MDA231 by RNA-seq.
The transcriptomic responses (fold change >2; p < 0.05) to these
two sets of concentrations showed some commonalities but
also many differences (Table S3). Each set was qualitatively
unique as determined by principal component analysis (Fig-
ure 3B). Of the two gene signatures, only that corresponding to
the intermediate CXCL12/IGF1 concentration was enriched in
CAF+ TN tumors, as determined by GSEA (Figure 3C). These
results suggest that endogenous signals in CAF+ tumors elicit
a response similar to that of cancer cells stimulated with limiting
concentrations of CXCL12 and IGF1 in vitro.CXCL12 and IGF1 Select for Src-Hyperactive Cancer
Cells
With these premises established, we modeled CXCL12/IGF1-
driven selection by subjecting cancer cells to long-term culture
in mitogen-poor media (0.2% fetal bovine serum) with or without
supplementation with CXCL12 and IGF1 (Figure 3D). Without
supplementation, very few colonies developed. These back-
ground clones (MDA231-0 cells) were pooled and expanded in
regular media. The level of pY416-Src in MDA231-0 cells was
the same as in the parental MDA231 cells (Figure 3E). With
CXCL12/IGF1 addition, more colonies grew (Figure S3B). After
expansion in regular growth media, the resulting cell population
(CXCL12/IGF1-selected MDA231 cells, MDA231-CI) showed a
gain in pY416-Src as determined by immunoblotting (Figure 3E)
and phospho-flow cytometry (Figure 3F). The level of pY416-Src
in MDA231-CI cells matched the upper quartile of the parental
MDA231 population (Figure 3A) and had a high SRS score (Fig-
ure 3G). Both parameters were stable over at least 25 population
doublings in regular culture conditions without CXCL12 or IGF1
additions (data not shown).
The gain in pY416-Src was verified by immunoprecipitation
with Src-specific antibody followed by anti-pY416-Src immuno-
blotting (Figure S3C). Src was not activated by CXCL12 and
IGF1, but it rather enhanced the activation of the PI3K-Akt
pathway by these cytokines, and this enhancement was
inhibited by the broad-spectrum Src kinase inhibitor dasatinib
(Figure S3D) (Zhang et al., 2009). In MDA231-CI cells, half-
maximal activation of Akt occurred at lower concentrations of
CXCL12 and IGF1 (Figure S3E). In sum, under restrictive growth
conditions, the presence of limiting concentrations of CXCL12
and IGF1 skewed the cancer cell population toward a prepon-
derance of clones with an intrinsically high level of activated Src.
CXCL12 and IGF1 Select for Bone Metastatic Clones
A prediction from the above findings is that breast cancer cells
with a high level of pY416-Src have a particular survival advan-
tage in the bone marrow because CXCL12 and IGF1 are rela-
tively more abundant in this tissue than in other organ sites
(Zhang et al., 2009). Indeed, when inoculated into the arterial
circulation of mice, the MDA231-CI cells were significantly
more metastatic to bone compared to parental MDA231 and
MDA231-0 cells (Figure 4A). Bone lesions formed by MDA231-
CI typically affected femora and vertebrae (Figure 4B).
MDA231-CI showed no gain in lung metastatic activity (Figures
S4A and S4B). The lesions formed by MDA231-CI cells were
mostly restricted to the bone marrow cavity, with little engage-
ment of osteoclasts or bone matrix destruction, as compared
to lesions formed by the aggressive bone metastatic derivative
MDA231-BoM1833 (Kang et al., 2003, 2005; Lu et al., 2009)
(Figure 4C). In line with this result, MDA231-CI showed little or
no gain in the expression of typical pro-osteolytic genes (Fig-
ure 4D). Thus, MDA231-CI cells spontaneously presented a
survival and outgrowth advantage in the bone marrow prior to
the onset of the osteolytic stage.
Several lines of evidence supported the specificity of these
effects. Src knockdown in MDA231-CI (Figures 4E, S4C, and
S4D) or administration of dasatinib 2 weeks after MDA231-CI
inoculation (Figure 4F) inhibited bone metastases. BoneCell 154, 1060–1073, August 29, 2013 ª2013 Elsevier Inc. 1063
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Figure 2. CAF Content in TN Tumors Is Linked to Bone Metastasis
(A) Box-whisker plots show the expression of various cancer-associated stromal signatures (Allinen et al., 2004) in TN tumors of the EMC-MSKdata set, according
to SRS status. The expression level of each signature in each tumor is represented by the average probe intensity of the genes comprising the signature. Dif-
ferences between SRS+ and SRS tumors were tested using Wilcoxon signed rank test. ***p < 0.0001. Myofibrobl., myofibroblast; n.s., no statistical difference.
(B) Venn diagram shows the overlap between the SRS-associated genes and the CAF signature genes, and identities of the six overlapping genes. p value was
calculated by Fisher’s exact test.
(C) Unsupervised hierarchical clustering of TN tumors from the EMC-MSK data set by CAF signature is shown. SRS+ status is indicated by red sticks above the
heatmap. Small arrows point to CXCL12 and IGF1 gene probes. Red and green bars left of the heatmap indicate genes that are over- or underexpressed in CAF
signature, respectively.
(legend continued on next page)
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Figure 3. CXCL12 and IGF1 Select for Src-
Hyperactive Cancer Cells
(A) Clonal heterogeneity of pY416-Src levels in the
MDA231 cell population is presented. A total of
100 random single-cell clones were subjected to
pY416-Src ELISA. Values were normalized to the
value of the parental population and ranked. The
pY416-Src level of the in-vitro-selected subpopu-
lation MDA231-CI is indicated by the red dot.
(B) Principal component analysis of gene expres-
sion profiles of MDA231 cells treated with CXCL12
and IGF1 at intermediate (30 plus 10 ng/ml) and
saturating (300 plus 100 ng/ml) concentrations is
presented. The first three principal components
are shown.
(C) GSEA of association between gene sets
induced by CXCL12/IGF1 at two different con-
centrations and CAF signature status in TN tumors
in EMC-MSK data sets is shown.
(D) Schematic illustrates the in vitro selection
procedure. Cell selection in media containing
0.2% serum lasted 3 weeks for MDA231 cells or
9 weeks for CN34 cells. CI, CXCL12/IGF1.
(E) pY416-Src levels of MDA231 subpopulations
resulted from in vitro selection as determined by
western immunoblotting. MDA231-P, parental
cells; MDA231-0, cells selected without CXCL12/
IGF1 addition; MDA231-CI, cells selected with
30 ng/ml CXCL12, 10 ng/ml IGF1.
(F) Histograms show pY416-Src distribution at the
single-cell level as determined by phospho-flow
cytometry of the indicated cell lines.
(G) SRS scores derived from gene expression
profiles of MDA231-0 and MDA231-CI cells are
presented. Scores are 0.76 and 1.0 for two
biological replicates of MDA231-0 cells, and 1.0
and 0.58 for MDA231-CI cells.
See also Figure S3 and Table S3.metastasis inhibition by dasatinib in MDA231 cells is specifically
mediated by inhibition of Src in the cancer cells (Zhang et al.,
2009). No EGF family members were present in the SRS+-asso-
ciated gene set or in the CAF signature, and MDA231 cell popu-
lations selected with EGF in low-serum media showed little gain
in pY416-Src content (Figure S4E) or bone metastatic activity
(Figures 4G and S4F).
Cancer cell clones with high Src activity (Srchigh, refer to Fig-
ure 3A) showed an intrinsically high bone metastatic ability inde-
pendently of osteolytic gene expression (Figures 4H, S4G, and
S4H), thus matching the phenotype of the CXCL12/IGF1-
selected MDA231-CI population. To test whether Src-hyperac-(D) GSEA revealed a strong association between SRS status and the enrichmen
(E) Representative examples and scores of aSMA IHC staining of TN breast tum
(F) Box-whisker plots show the CAF signature scores (see Experimental Procedure
sample size of each category are indicated. Statistical significance is assessed u
(G) Box-whisker plots show the expression of CAF signature in 65 breast cancer m
indicated in parentheses. The expression in bone metastases was significantly h
(H and I) Kaplan-Meier plots illustrate cumulative bone (H) and lung (I) metastasis
signature score is used as a cutoff to separate CAF+ and CAF cases. Cases
analysis are all TN samples with available microarray data. Numbers of relapse ca
calculated according to log rank test.
See also Figure S2.tive cells show elevated bone metastatic ability from the
orthotopic site, we labeled Srchigh cells with turbo-GFP, which
generates a strong fluorescence signal that facilitates visualiza-
tion of lesions. Nine weeks after mammary tumor implantation,
no significant difference was observed in the size of primary
tumors formed by Srchigh or Srclow cells (Figure S4I) or in the
accumulation of cancer cells in the lungs (Figure S4J). Notably,
Srchigh mammary tumors showed a much higher rate of sponta-
neous bone metastases compared to Srclow tumors (Figures 4I
and 4J), and the proportion of GFP+ cancer cells in bonemarrow
aspirates subjected to flow cytometry (Figure S4K) was much
higher in mice bearing Srchigh tumors (Figure 4K).t of CAF signature genes.
or samples are shown. Scale bar, 200 mm.
s) in tumor tissuemicroarrays withmatchedmicroarray data. The definition and
sing one-way ANOVA.
etastasis samples from different sites. The number of metastases at each site is
igher (*p < 0.0001, Wilcoxon test) compared to all other sites combined.
-free survival in patients with TN according to CAF signature. The median CAF
without clinical follow-up information are omitted. The cases included in this
ses over total cases in each category are indicated in parentheses. p value was
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Figure 4. CXCL12/IGF1-Selected Cells Are
Highly Metastatic to Bone
(A) Bone metastasis formation after intracardiac
inoculation of the indicated MDA231 subpop-
ulations as monitored by quantitative luciferase
bioluminescence is presented. Representative
images of mice in each group are shown. Error
bars, SEM (n = 8–10 in each group).
(B) H&E of bone lesions derived from experiments
in (A) is presented. Lesions from hindlimbs and
vertebral bones are indicated by arrows. Scale
bars, 1 mm.
(C) Bone lesions formed byMDA231-CI cells or the
highly osteolytic population MDA231-BoM1833
cells (Kang et al., 2003) are shown. Left panels
present low-magnification H&E. Middle panels are
high-magnification H&E showing the interface
between metastasis and bone matrix. Small
arrows indicate active osteoclasts as revealed by
tartrate-resistant phosphatase staining. Scale
bars, 100 mm. Right panels are radiographic
images of representative bone lesions. Arrow
points to a large osteolytic lesion.
(D) Expression of bone osteolytic genes (Kang
et al., 2003; Lu et al., 2009) in the indicated cell
lines is shown. Error bars, SEM.
(E) Effect ofSrc knockdownon thebonemetastasis
activity of MDA231-CI cells is presented. Error
bars, SEM (n = 8–10 in each group). ctrl, control.
(F) Dasatinib treatment inhibits bone metastasis
by MDA231-CI cells. Dasatinib (10 mg/kg) was
administered daily by oral gavage starting 14 days
after injection. Error bars, SEM (n = 8–10 in each
group).
(G) Bone metastasis assays of EGF-selected
MDA231 subpopulations andMDA231-CI cells are
shown. Error bars, SEM (n = 8–10 in each group).
(H) Bone metastasis activity of pooled Srchigh and
Srclow clones isolated from MDA231 parental
population is presented. Error bars, SEM (n = 8–10
in each group).
(I and J) Spontaneous bone metastases from
mammary tumors formed by different GFP+Srchigh
and Srclow clones are presented. Representative
fluorescence images of hindlimbs (I) and spine (J)
are shown. GFP+ signals indicate metastasis foci.
(K) Quantification of bone metastases from (I) by
flow cytometry of bone marrow flush is presented.
Percentages of cancer cells out of total bone
marrow content are shown.
See also Figure S4.CXCL12 and IGF1 Select for Clones that Persist in the
Bone Marrow
To further characterize the phenotype selected by CXCL12 and
IGF1, we applied the in vitro selection protocol to the CN34
model, which is more indolent than MDA231 and allows analysis
of the latent metastasis state (Zhang et al., 2009). Similar enrich-
ment of Src-hyperactive clones was seen after long-term culture
of CN34 cells in CXCL12/IGF1-supplemented media (Figures 5A
and S5A). We determined the load of human cells in the bone
marrow by quantitation of human b2-microglobulin (B2M)
mRNA levels (Figure 5B), which can detect as few as ten human
cancer cells in 5 3 106 mouse cells (Figure S5B). Eight weeks1066 Cell 154, 1060–1073, August 29, 2013 ª2013 Elsevier Inc.after inoculation of the cells into the arterial circulation of mice,
the CXCL12/IGF1-selected CN34 cells (CN34-CI) had a superior
ability to persist in the bone marrow (Figure 5C). Under experi-
mental conditions that allow the incipient outgrowth of these
cells in the marrow, administration of dasatinib suppressed the
outgrowth (Figure 5D).
Transcriptional Shift of Mammary Tumors under a
Mesenchymal Stroma
We investigated whether supplementing experimental mam-
mary tumors with mesenchymal cells would lead to the selec-
tion of Src-hyperactive cancer cells and a gain in bone
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Figure 5. CXCL12 and IGF1 Select for Clones that Persist in the Bone
Marrow
(A) Subpopulations of CN34 cells were selected and examined for Src activity
using the same procedures as described in Figures 3D and 3E.
(B and C) CN34-0 and CN34-CI cells were inoculated into the left ventricle of
7-week-old Bg/nu mice (105 cells per mouse). Eight weeks later, mice
were sacrificed, and bone marrow samples were prepared. RT-qPCR
was performed to quantify human B2M mRNA. Mouse-specific b-actin
(Actb) was used for normalization. Each dot in the plot represents one
hindlimb.
(D) Dasatinib treatment inhibits the outgrowth of CN34-CI bone micro-
metastases. Cells were injected into 4-week-old Bg/nu mice (105 cells
per mouse). Dasatinib (10 mg/kg) was administered daily by oral
gavage, starting 3 days after injection. Error bars, SEM (n = 8–10 in each
group).
See also Figure S5.metastatic activity. To this end, we used bone marrow-derived
human mesenchymal stem cells (MSCs) as a source of mesen-
chymal stromal signals. MSCs express CXCL12 (Me´ndez-Ferrer
et al., 2010), undergo CAF-like differentiation in response to
cancer cell signals (Mishra et al., 2008), and contribute to the
stroma in primary tumors (Karnoub et al., 2007; Quante et al.,
2011). In their basal state, MSCs secreted CXCL12, and when
stimulated with cancer cell-conditioned media, MSCs addition-
ally secreted IGF1 (Figures S6A and S6B). In contrast, the
breast cancer cells did not secrete CXCL12 or IGF1. Transcript
levels of CXCL12 and IGF1 were in line with these results
(Figure S6C).
To assess whether MSC supplementation would recapitulate
the key features of humanCAF+ breast tumors, we transcription-
ally profiled cancer cells in MSC-supplemented experimental
tumors in situ. This was achieved by engineering MDA231 cells
to express a ribosomal protein L10a fused to EGFP (EGFP-
L10a). The expressed EGFP-L10a is incorporated into the
cancer cell ribosomes, allowing the specific retrieval of cancer
cell transcripts from tumor lysates by polysome immunoprecip-
itation with anti-EGFP antibody (Figure 6A; translating ribosome
affinity purification [TRAP]). TRAP (Heiman et al., 2008) enables
RNA-seq analysis of the cancer cell transcriptome from freshlyexcised tumors without intervening cell isolation steps that could
confound the results.
MDA231 cells expressing EGFP-L10a were implanted alone
as a control or MDA231 admixed with MSCs at a 1:1 ratio
into the mammary fat pads of mice. RNA-seq analysis of the
TRAP samples showed that tumor supplementation with
MSCs caused a transcriptomic shift in the cancer cells that
resembled the shift associated with CAF+ status in clinical
tumor samples (Figures 6B and 6C). Consistently, MSC-sup-
plemented tumors showed a 3- to 10-fold increase in the
proportion of cells staining positive for the CAF marker aSMA
(Figure 6D) and a higher level of CXCL12 and IGF1 immuno-
staining (Figures 6E and 6F). The TRAP RNA-seq data revealed
no ribosome-associated CXCL12 or IGF1 transcripts in cancer
cells (Figure S6D).
The gene expression profile of cancer cells from MSC-
supplemented tumors resembled the profile of MDA231
cells treated with limiting CXCL12 and IGF1 concentrations
(Figure 6G). This similarity was further validated by Ingenuity
pathway analysis of the differentially expressed genes.
Upstream regulator analysis revealed CXCL12- and IGF1-
induced signaling and their downstream PI3K-Akt signaling in
the cancer cells (Figure 6H). These genes are enriched in
biological processes associated with metastasis and bone
biology (Figure 6I). Thus, the model tumors cotransplanted
with MSCs gained a bioactive CXCL12/IGF1 microenvironment
and response features that are characteristic of CAF+ TN
tumors.
A Mesenchymal Stroma Selects for Bone Metastatic
Cells in Mammary Tumors
Cancer cells were purified from MDA231 mammary tumors,
expanded in culture for several passages, and characterized
(Figure 7A). Cancer cells recovered from MSC-supplemented
tumors showed a high level of pY416-Src compared to popula-
tions derived from control tumors (Figures 7B and 7C). Treat-
ment of the mice with inhibitors of the CXCL12 receptor
CXCR4 (AMD3100) (Hatse et al., 2002) and of the IGF1 receptor
(IGF1R) (BMS754807) (Carboni et al., 2009) (Figure S7A) during
tumor growth prevented the accumulation of pY416-Srchigh cells
(Figures 7B and 7C), without significantly affecting overall tumor
growth. Importantly, cancer cell populations derived from the
MSC-supplemented tumors were significantly more metastatic
to bone (Figure 7D), without a gain in lung-colonizing ability
(Figure 7E).
Cancer cell populations derived from mice treated with
IGF1R and CXCR4 inhibitors were poorly metastatic to bone
(Figure 7D). To confirm the specificity of these effects, we
knocked down CXCR4 and IGF1R simultaneously in MDA231
cells (Figures 7F, 7G, and S7B). Knockdown of the two
receptors did not affect the level of pY416-Src in MDA231
cells (Figure 7G), but it prevented MSCs from selecting for
carcinoma clones with high pY416-Src content (Figures 7H
and 7I). The ability of admixed MSCs to select for clones with
high pY416-Src and bone metastatic ability was confirmed
in the CN37 cell line (Figures S7C and S7D). Furthermore,
primary CAFs isolated from a human breast tumor secreted
CXCL12 and IGF1 (12.6 ± 0.2 ng/ml and 0.44 ± 0.02 ng/ml,Cell 154, 1060–1073, August 29, 2013 ª2013 Elsevier Inc. 1067
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Figure 6. Transcriptional Shift in Mammary Tumors under a Mesenchymal Stroma
(A) Isolation of cancer cell-specific, polysome-associated transcripts by TRAP for RNA-seq analysis is shown.
(B and C) Principal component analyses of polysome-associated transcriptomic data of MDA231 from xenograft tumors and transcriptomic data of TN
tumors from a clinical cohort are presented. MDA231mammary tumors were formedwithMSC supplementation (+MSC) or without (MSC) supplementation; TN
tumors scoring as CAF+ or CAF based on the CAF signature were from the EMC-MSK cohort. Principal component 1 maximally separates CAF+ from
CAF tumors and was used to generate the plot in (C). p value was calculated with t test.
(D–F) Histological analysis of mammary tumors generated with or without admixedMSCs is presented. (D) IHC staining of aSMA is shown. (E) Immunofluorescent
(IF) staining of IGF1 is presented. (F) IF staining of CXCL12 and DAPI nuclear staining are shown. Scale bars, 100 mm.
(G) Principal component analysis using combined data of TRAP RNA-seq of MDA231 in vivo mammary tumors and that of in vitro CXCL12+IGF1 treatment
(Figure 3C) is presented. The results show that intermediate CI samples fall closest to MSC+ tumors. Saturating CI samples, on the other hand, are dissimilar.
Intermediate CI, intermediate [CXCL12, IGF1]; saturating CI, saturating [CXCL12, IGF1], refer to Figure 3C.
(H and I) Ingenuity pathway analysis of the differentially expressed genes from polysome-associated transcriptomic data of MDA231 mammary tumors in (A)–(C)
is shown. IGF1, CXCL12, and AKT signaling are predicted to be activated based on upstream regulator analysis (H). Metastasis-related biological processes are
enriched (I).
See also Figure S6.respectively, after 96 hr in culture) and selected for pY416-Src-
enriched MDA231 cells when admixed in mammary tumors in
mice (Figure 7J). The evidence therefore supports a model in
which CAFs in mammary tumors cause an accumulation of1068 Cell 154, 1060–1073, August 29, 2013 ª2013 Elsevier Inc.stromal CXCL12 and IGF1, and these factors act directly on
cancer cells to drive the selection of Src-hyperactive clones
that are automatically primed for adaptation to the bone meta-
static microenvironment.
DISCUSSION
Preselection of Bone Metastatic Seeds by the Primary
Tumor Stroma
TN breast cancer is a major and particularly aggressive subtype
of the disease. Unlike hormone receptor-positive breast tumors,
which have a marked tendency to metastasize mainly in bone,
TN tumors as a whole prominently metastasize in nonskeletal
organs including lungs, liver, and brain (Dent et al., 2009). We
have focused here on a subset of TN tumors that deviates
from this trend in that it also metastasizes prominently in bone.
Cancer cells from this subset are characterized by a high level
of Src activity and a high sensitivity to PI3K-Akt pathway activa-
tion by CXCL12 and IGF1 (Zhang et al., 2009). By identifying the
primary tumor stroma as a driver of the emergence of this pheno-
type, the present work illuminates the larger question of how
organ-specific metastatic traits may arise in cancer.
Our evidence suggests that, when the stroma of a TN breast
tumor is rich in mesenchymal cells, it selects for cancer clones
that are fit to thrive on the CAF-derived cytokines CXCL12 and
IGF1 (Figure 7K). This selection process leads to a gain in the
predisposition of cancer cells for metastasis to bone, a site
that is relatively rich in stromal CXCL12 and IGF1 compared to
other metastasis target sites. In other major subtypes of breast
cancer, Src activation is integral to the oncogenic drivers like
ERa (Collins and Webb, 1999) and ERBB2 (Ishizawar et al.,
2007; Zhang et al., 2011) and might similarly contribute to
bone metastatic tropism of these tumors.
The clinical evidence also links the CAF content with a predis-
position for bone metastasis in TN tumors. In multiple human
breast cancer cohorts, TN tumors that score high for cancer
cell Src signature present a mesenchymal-rich stroma both
based on a CAF gene expression signature and on marker
aSMA immunostaining. These tumors are also characterized
by the expression of CXCL12 and IGF1, factors that are mainly
of mesenchymal origin in the tumors. Each of these traits in
turn is individually associated with an elevated rate of bone
relapse.
Our experimental evidence suggests that CXCL12 and IGF1
can drive TN cancer cell populations toward enrichment for
clones that have a constitutively high level of Src activity and
bone metastatic ability. Three essential premises for the clonal
evolution of a cancer cell population are fulfilled under these
conditions. First, Src activity in the cancer cells acts as a select-
able trait that confers heightened sensitivity to CXCL12 and IGF1
as activators of PI3K-Akt survival signaling. Second, this trait
ranges widely in the clonally heterogeneous cancer cell popula-
tion that we examined. Third, the positive selectors for this trait,
CXCL12 and IGF1, are present at limiting concentrations in the
tumor microenvironment, as determined by analysis of breast
tumor transcriptomic data using dose-specific CXCL12/IGF1
response classifiers. When modeled in vitro, the end result of
this process is the emergence of Src-hyperactive clones with
an intrinsically high ability to survive and outgrow in the
CXCL12/IGF1-rich environment of the bone marrow.
Further support for this model comes from our experiments
with orthotopically implanted mammary tumors in mice supple-
mented with MSCs or CAFs. We show that mesenchymalsupplementation shifts the transcriptome of the cancer cell
population in a tumor toward a profile resembling that of CAF+
TN human tumors. Moreover, enriching tumors with MSCs
caused CXCL12/IGF1-like stimulation in the cancer cells, and
the level of this stimulation at the transcriptome reflected limiting
concentrations of the cytokines and was comparable to that
observed in CAF+ human tumors. These conditions skew the
cancer cell population toward clones with intrinsically high levels
of Src activity and a heightened capacity for bone metastasis.
The accumulation of these Src-hyperactive, bone metastatic
cells was dependent on CXCR4 and IGF1R expression in the
cancer cells and was inhibited by administration of pharmaco-
logic inhibitors of these receptors.
The Primary Tumor Stroma as a Determinant of
Metastatic Tropism
The evidence supports a model in which a TN tumor stroma rich
in mesenchymal cytokines CXCL12 and IGF1 skews the carci-
noma population toward a preponderance of clones with a
high level of activated Src and a predisposition to grow in the
bone marrow, a soil that is rich in CXCL12 and IGF1 compared
to lung, brain, and other metastasis target tissues. Thus, similar-
ities between the cytokine microenvironment of CAF-rich pri-
mary tumors and that of the bone marrow make the preselected
metastatic seeds compatible with this target tissue (Figure 7K).
Stromal cells that produce CXCL12 and IGF1 in a primary tumor
are not necessarily superior to other stromal components in sup-
porting primary tumor growth but are superior in preselecting
bone metastatic seeds. Our present findings are limited to the
case of bone metastasis tropism in TN breast cancer. It will be
important to determine whether these phenomena occur also
in other bone metastatic tumor types and whether other stromal
components such as leukocytes may similarly select cancer
cells with metastatic tropism for other organs.
The ability of the primary tumor stroma to drive the selection of
organ-specific metastatic cells is distinct from previously
described roles of stromal signals in tumor progression (Chung
et al., 2010; Hanahan and Coussens, 2012; Hanahan and Wein-
berg, 2011; Joyce and Pollard, 2009), including roles in the resis-
tance to stress and chemotherapy (Acharyya et al., 2012; Calo´n
et al., 2012; DeNardo et al., 2011; Gocheva et al., 2010; Qian
et al., 2011). These previously described stromal signals do
not explain how organ-specific metastatic traits and their asso-
ciated gene signatures emerge in primary tumors. The formation
of premetastatic niches by tumor-derived systemic signals that
condition distant organs for seeding by disseminated cancer
cells also does not entail an acquisition of specific metastatic
traits in the primary cancer cell population itself (Kaplan et al.,
2005). The mechanism of metastasis seed preselection identi-
fied here may coexist with other effects of the tumor stroma
but is distinct in that it selects for organ-specific metastatic
traits.
The interplay between a primary tumor and a specificmetasta-
tic site revealed by the present work expands current views on
the dynamic nature of metastasis. Coupled with processes of
tumor self-seeding whereby previously disseminated cells may
repopulate and expand in their tumor of origin (Kim et al.,
2009), seed preselection at the primary site may further swayCell 154, 1060–1073, August 29, 2013 ª2013 Elsevier Inc. 1069
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Figure 7. A Mesenchymal Stroma Selects for Bone Metastatic Cells in Mammary Tumors
(A) Experimental strategy is presented.MDA231 cells alone or admixedwithMSCswere implanted inmammary fat pads. One set ofmicewas treatedwith CXCR4
inhibitor (CRi, AMD3100) and IGF1R inhibitor (IRi, BMS754807). After reaching 1 cm3, tumors were excised, and cancer cells were recovered and expanded in
culture for testing.
(B andC) pY416-Src levels in cancer cell lines from individual mammary tumors formed byMDA231 under the indicated conditions are presented: immunoblot (B)
and quantification (C).
(D and E) Bone metastasis (D) and lung colonization (E) activity of the pooled cell lines derived in (B) is illustrated. Normalized bioluminescence signals were
quantified at 21 days (D) or 30 days (E) after inoculation. Error bars, SEM (n = 8–10 in each group).
(legend continued on next page)
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the organotropic metastatic traits of a primary tumor mass with
clinically manifest consequences. Our results also imply that
breast cancer cases with a fibroblast-rich stroma or with incip-
ient bone metastasis may benefit from therapies that target the
PI3K-Akt cell survival pathway or its amplifier Src for the eradica-
tion of disseminated disease.
EXPERIMENTAL PROCEDURES
Computational Analyses of Clinical Data Sets
SRS was derived as previously described (Zhang et al., 2009). Stratification of
the 615 patients with SRS, ER, and ERBB2 in the Erasmus Medical Center/
Memorial Sloan-Kettering Cancer Center (EMC-MSK) cohort (GSE2603,
GSE5327, GSE2034, and GSE12276 data sets) was done with unsupervised
clustering implemented by the ‘‘heatmap.2’’ command of the ‘‘gplots’’ pack-
age of R statistical programming software. ER+, HER2+ (ER/HER2+), and
TN (ER/HER2) subtypes were determined either using the clinical annota-
tion associated with the data set (if applicable) or by the transcript levels
of ESR1 and ERBB2, respectively. The continuous scores of SRS were
computed with the sum of Z scores of 159 SRS genes and the DART algorithm
(Jiao et al., 2011).
To identify genes associated with SRS status, SRS was applied to EMC-
MSK, Transbig (GSE7394), Uppsala (GSE4922), and Stockholm (GSE1456)
data sets. SRS+ and SRS tumors were compared within the TN subset of
each data set. Genes that are expressed at a significantly higher level in
SRS+ tumors (p < 0.001 and fold change >2 for EMC-MSK, and p < 0.05 for
the other three, t tests with Welch correction) were identified. To compute
the combined p value for each gene across all four data sets, we employed
Fisher’s combination (see Extended Experimental Procedures). To further
evaluate the significance of these genes, we utilized the TCGA cohort as a vali-
dation data set (https://tcga-data.nci.nih.gov/tcga/tcgaDownload.jsp). We
examined the p values and FDR of the 43 genes by comparing TN/SRS+
tumors with TN/SRS tumors. Both p values and FDR were computed using
the ‘‘siggene’’ package in R statistical software based on SAM algorithm
(Tusher et al., 2001). All 38 genes that can be mapped to TCGA platform reach
significance (Table S2).
Gene signatures associated with CAFs were obtained from a previous study
by Allinen et al. (2004).We used unsupervised hierarchical clustering, themean
expression of CAF genes, and GSEAs to determine the CAF status of a tumor.
Other stromal cell types were analyzed using the same approaches (see
Extended Experimental Procedures for details).
For analyses of correlation between somatic PIK3CA mutation status and
SRS, somatic mutation data from the TCGA data set were matched with
mRNA expression data. The overlap between PIK3CAmutation and SRS+ sta-
tus was assessed with Fisher’s exact test.
To examine the correlation among CAF gene expression signature, SRS,
and aSMA immunohistochemical (IHC), we divided the IHC staining into
three categories depending on the percentage of aSMA+ fibroblastic cells
(see Figure 2E). CAF and SRSs were then evaluated as continuous scores
(described above) in different categories (Figures 2F and S2C). The statistical
difference among the three groups was assessed by one-way ANOVA imple-
mented by R.(F) Flow cytometry analysis of CXCR4 surface expression in MDA231 with two ind
to control (ctrl) is shown.
(G) Western immunoblot analysis of IGF1R and pY416-Src protein levels in two D
(H and I) pY416-Src levels in cancer cell lines frommammary tumors formed by co
are shown: immunoblot (H) and quantification (I).
(J) pY416-Src levels of cancer cell lines from individual mammary tumors formed
presented.
(K) A model of bone metastasis seed preselection by a mesenchymal-rich stroma
and nonmesenchymal stromal cells, respectively. As the tumor grows in a mesen
preponderance of clones that thrive on mesenchymal cytokines such as CXCL1
IGF1-rich bone marrow.
See also Figure S7.Cancer-Cell-Specific Polysome-Associated Transcript Profiling
MDA231 cells were engineered to express an EGFP-L10a construct (Heiman
et al., 2008). For the analysis of cytokine responses in vitro, cancer cells
were treated for 6 hr with 30 ng/ml CXCL12 and 10 ng/ml IGF1 or with
300 ng/ml CXCL12 and 100 ng/ml IGF1. For the analysis of gene responses
to MSCs in vivo, breast cancer cells were injected into the mammary fat
pads of mice with or without a 1:1 admixture of MSCs, and tumors were har-
vested 3 weeks later. Cultured cells or tumors were lysed and immediately
subjected to TRAP as previously described by Heiman et al. (2008) with mod-
ifications described in the Extended Experimental Procedures.
For RNA-seq data analysis, the raw sequence data (FASTQ files) were map-
ped using TopHat (v.1.4.0) (Trapnell et al., 2009) to the human genome (hg19
build) available from UCSC. Of all reads, 89% were uniquely mapped on
average. Gene level expression counts were determined using HTSeq and
normalized with DESeq (Anders and Huber, 2010). The normalized counts
were then log transformed for analysis. Genes with zero counts were still
assigned as zeros after log transformation to avoid exceptions in program-
ming. The approaches of subsequent analyses are described in the Extended
Experimental Procedures.
Animal Studies
All animal work was done in accordance with a protocol approved by the
MSKCC Institutional Animal Care and Use Committee. Intracardiac injections
of cancer cells for bone metastasis assays, intravenous injections for lung
colonization assays, and orthotopic injections for mammary tumor formation
were performed as previously described by Kang et al. (2003) and Minn
et al. (2005). Animals were imaged weekly by bioluminescence imaging
(IVIS; Xenogen). For quantification of bioluminescence signal, all signals
were normalized to the signals at day 0 right after injection. For bone metasta-
ses, signals at hindlimbs and vertebrae were jointly quantified. Osteolytic
lesions were visualized by X-ray radiography and were identified on radio-
graphs as demarcated radiolucent lesions in the bone. Cancer cells from
mammary tumors were retrieved by enzyme digestion (0.125% collagenase
III and 0.1% hyaluronidase in DMEM/F12 medium) and GFP sorted for further
experiments or inoculation into mice. Dasatinib (Bristol-Myers Squibb) was
administered by daily oral gavage with a dose of 10 mg/kg in PBS.
AMD3100 (Tocris Bioscience; catalog 3299), a CXCR4 inhibitor, was adminis-
tered by subcutaneous injection twice a day at 2.5 mg/kg in PBS. BMS754807
(ChemieTek; catalog CT-BMS75), an IGF1R inhibitor, was administered by
daily oral gavage at 6.25 mg/kg in polyethyleneglycol:H2O (4:1).
Primers for SYBR Green Mix reaction (Thermo Scientific) are listed in
Table S4.
ACCESSION NUMBERS
Microarray and RNA-seq data can be obtained online with GEO accession
numbers GSE39102, GSE43296, GSE43306, and GSE47389.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Extended Experimental Procedures, seven
figures, and four tables and can be foundwith this article online at http://dx.doi.
org/10.1016/j.cell.2013.07.036.ependent double knockdowns (DKD1, DKD2) of CXCR4 and IGF1R compared
KD cell lines is presented.
ntrol MDA231 (ctrl) or two DKD cell lines with or without MSC supplementation
by MDA231 cells with or without admixed CAFs from a human breast tumor are
in the mammary tumor is shown. Blue and gray cells represent mesenchymal
chymal-rich microenvironment, the cancer cell population is skewed toward a
2 and IGF1, which selects for a predisposition to metastasize in CXCL12- and
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